FDA commissioner highlights efforts to improve expanded access program
The agency also launched in information website about Right to Try, which President Donald Trump signed into law in May.
Gottlieb at BIO: FDA developing processes around right-to-try law
FDA commissioner gives clues of agency's right-to-try strategy in Q&A session during chat with BIO President Jim Greenwood.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Right-to-try law intended to weaken FDA, bill’s author tells agency commissioner
The law, which President Trump signed this week, allows patients to receive experimental drugs without FDA oversight.
Right-to-try bill passes in House, heads to president’s desk for signature
The legislation, which has drawn criticism from researchers, patient advocates and industry, would enable patients to request experimental drugs while bypassing the FDA.
Right to Try legislation to ease rules on experimental drug access falters in House vote
Although the Senate handily passed a proposal authorizing Right to Try in August, the House vote failed to get a two-thirds majority with a vote of 259 to 140.
Senate OKs Right to Try legislation as part of FDA User Fee Reauthorization bill
The Senate approved the feel good legislation which was hotly debated at the MedCity CONVERGE conference this week.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Pence meets with “Right to Try” leaders at White House
Should unproven drugs be made available to terminally ill patients? Vice President Mike Pence looks to be preparing that discussion for the national stage, hosting "Right to Try" advocates at the White House.
As right-to-try laws gain wider adoption, is stronger federal legislation needed?
The renewed interest in compassionate use — which first emerged as a national issue during the AIDS crisis of the 1980s — also has spurred pharmaceutical companies to ramp up “expanded access” programs.
Patient advocates launch offensive against ICER over drug costs
A forum convened by patient advocates will serve as the launching event for the ICER Watch patient portal, which will track the movements of the Institute for Clinical and Economic Review, which last month released a report on the effectiveness of treatment options for multiple myeloma.